Echo Therapeutics pursues CE mark for wireless glucose monitoring system; Volcano lowers 2014 guidance;

@FierceMedDev: Appeals court reaffirms injunction on Boston Scientific's Guidezilla catheter. More | Follow @FierceMedDev

@MarkHFierce: Detailed medical imaging of the skin is drawing investor interest in the U.K. Release | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: O.C. medical device firm sees great potential in Indian market, expands sales. More | Follow @EmilyWFierce

> Volcano ($VOLC) now expects revenue to grow 4% to 6% in 2014, down from earlier predictions of 9% to 11% growth. The maker of surgical tools to help diagnose and treat coronary and peripheral vascular disease said it expects a softer global market and fewer procedures in Japan. Item

> Echo Therapeutics submitted a CE mark application for its Symphony CGM System, a non-invasive, wireless continuous glucose monitoring system. Item

> The U.K.'s Michelson Diagnostics nailed down $3.25 million in new financing, in part to support sales expansion in Germany for its VivoSight medical imaging system, which non-invasively looks at all layers of the skin in precise detail. Item

> Providence Medical Technology has nailed down 5 U.S. patents in recent months affecting joint implants and how they are placed inside the body. Item

> Excelsior Medical gained a 510(k) clearance for its disinfection cap, which works to disinfect a valve surface for up to a week. Item

> Enable Injections of Franklin, OH, is trying to bring a painless drug injector to market before some much larger rivals do the same. Story

Biotech News

@FierceBiotech: Merck's fast and furious MK-3475 #immunotherapy team guns for a quick approval. Story | Follow @FierceBiotech

@JohnCFierce: Interesting to see Sanofi and Roche going deeper into RNAi as Merck bails out, takes a big writeoff for Sirna. Makes sense, though. In or out. | Follow @JohnCFierce

@DamianFierce: With $125M Alexion deal, Moderna has pulled in more than $500M over the past year and change. More | Follow @DamianFierce

@EmilyMFierce: European industry-academic partnership seeks miRNA therapies for neurodegenerative diseases. Article | Follow @EmilyMFierce

> GSK dumps a failed muscular dystrophy drug back in Prosensa's lap. Story

> Cell Therapeutics buoyed as Novartis deals are terminated. More

> Sanofi grabs a $700M stake in Alnylam as it ups the ante on RNAi. News

Pharma News

@FiercePharma: AC Immune begins first trial of a tau-targeting Alzheimer's vaccine. Story from FierceVaccines | Follow @FiercePharma

@TracyStaton: And still FiercePharma's best-read special report: Top 10 Drug Patent Losses of 2014. Report | Follow @TracyStaton

@EricPFierce: There are 3,000 compounding pharmacies making sterile drugs. Just 11 have volunteered for FDA oversight. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Adcock Ingram forges ahead with its African expansion while CFR deal stalls. Friday's story | Follow @CarlyHFierce

> FDA's latest action further imperils Ranbaxy's U.S. sales. Story

> Look for an M&A scramble in 2014, with pharma chasing deals at ever-higher prices. Report

> Chinese corruption probe expands as officials detain former Sinopharm exec. More

CRO News

> Quintiles partners up to boost its commercialization business. More

> Theorem aligns with BioTelemetry to dial up its cardiac market share. Report

> CROS NT buys into biometrics with its latest acquisition. News

> Pfizer taps risk-sharing researcher Avillion for cancer PhIII. Story

> JSS eyes Canadian dominance with buyout of rival CRO. Article

> GoBalto goes global with expansion into U.K. and Singapore. Item

Biotech IT News

> New York Genome Center taps U. of Buffalo for computing horsepower. Report

> Pfizer trialing video game designed to diagnose Alzheimer's. Item

> Merge wipes $15M from backlog after discovering ex-employee faked contracts. News

> Merck invests in an FDA-cleared mobile diabetes management business. Article

> Analyst: CROs like Covance and Icon will take the lead on IT and genomics. Story

> Early Google investor picks Maverix from the genome data analysis crowd. More

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.